Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.56 -4.1%	$2.03	$1.60 ▼ $2.77	$982.55M	1.01	1.75 million shs	8.54 million shs
IMTX Immatics	$6.42 +1.3%	$6.00	$3.30 ▼ $13.09	$780.35M	0.93	749,853 shs	198,023 shs
NLTX Neoleukin Therapeutics	$20.35 -4.1%	$20.43	$2.03 ▼ $14.36	$191.25M	1.11	50,104 shs	133,288 shs
NUVB Nuvation Bio	$2.32 +3.6%	$2.20	$1.54 ▼ $3.45	$789.40M	1.35	4.18 million shs	4.26 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	+16.09%	+32.18%	+27.75%	+30.88%	+21.36%
IMTX Immatics	+2.59%	-4.08%	+6.20%	+46.08%	-45.01%
NLTX Neoleukin Therapeutics	0.00%	-2.57%	-0.98%	+19.89%	-40.38%
NUVB Nuvation Bio	-2.83%	-3.25%	+1.59%	+2.05%	-21.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.4057 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.0	1.3
IMTX Immatics	2.853 of 5 stars	3.6	4.0	0.0	0.0	2.8	1.7	0.0
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	1.9723 of 5 stars	3.6	0.0	0.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
IMTX Immatics	3.20	Buy	$14.67	128.45% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
NUVB Nuvation Bio	3.17	Buy	$7.33	216.09% Upside

Current Analyst Ratings Breakdown

Latest NLTX, IMTX, NUVB, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	8.35	N/A	N/A	$2.90 per share	0.88
IMTX Immatics	$168.65M	4.63	$0.25 per share	25.29	$5.12 per share	1.25
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
NUVB Nuvation Bio	$7.87M	100.31	N/A	N/A	$1.37 per share	1.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.05	51.20	85.33	N/A	14.19%	-3.78%	-3.62%	N/A
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-14.73%	-4.52%	-3.34%	8/12/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
NUVB Nuvation Bio	-$567.94M	-$0.63	N/A	N/A	N/A	-1,413.43%	-46.14%	-36.04%	N/A

Latest NLTX, IMTX, NUVB, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2025	IMTX Immatics	-$0.38	N/A	N/A	N/A	$13.05 million	N/A
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/7/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	-$0.17	N/A	-$0.17	$0.42 million	$4.83 million
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	24.65	23.53
IMTX Immatics	N/A	10.28	10.28
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
NUVB Nuvation Bio	0.13	9.39	9.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
IMTX Immatics	64.41%
NLTX Neoleukin Therapeutics	52.37%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
IMTX Immatics	N/A
NLTX Neoleukin Therapeutics	1.58%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	383.81 million	357.32 million	Optionable
IMTX Immatics	260	121.55 million	N/A	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable

NLTX, IMTX, NUVB, and CRON Headlines

Recent News About These Companies

Nuvation Bio (NYSE:NUVB) Downgraded by Wall Street Zen to "Sell"

August 12 at 2:55 AM | americanbankingnews.com

Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

August 11 at 8:54 AM | marketbeat.com

Royal Bank Of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $7.00

August 10 at 3:09 PM | marketbeat.com

Wedbush Reaffirms Their Buy Rating on Nuvation Bio (NUVB)

August 10 at 12:59 PM | theglobeandmail.com

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 10 at 7:58 AM | theglobeandmail.com

Wall Street Zen Downgrades Nuvation Bio (NYSE:NUVB) to Sell

August 10 at 3:16 AM | marketbeat.com

Royal Bank Of Canada Issues Positive Forecast for Nuvation Bio (NYSE:NUVB) Stock Price

August 10 at 2:49 AM | americanbankingnews.com

H.C. Wainwright Sticks to Their Buy Rating for Nuvation Bio (NUVB)

August 9 at 4:56 PM | theglobeandmail.com

NUVB Sales Jump 1,043% on Drug Launch

August 7, 2025 | aol.comA

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | gurufocus.com

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | businesswire.com

Nuvation Bio (NUVB) to Release Quarterly Earnings on Thursday

August 5, 2025 | americanbankingnews.com

Brokerages Set Nuvation Bio Inc. (NYSE:NUVB) Target Price at $7.17

August 4, 2025 | americanbankingnews.com

Nuvation Bio Inc. (NYSE:NUVB) Given Average Rating of "Buy" by Brokerages

August 2, 2025 | marketbeat.com

Nuvation Bio (NUVB)’s Taletrectinib Selected as Preferred Agent for Cancer Treatment

August 1, 2025 | finance.yahoo.com

GSA Capital Partners LLP Has $1.16 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB)

August 1, 2025 | marketbeat.com

RBC Capital Maintains a Buy on Nuvation Bio (NUVB) With a $6 PT

August 1, 2025 | msn.com

Institutional investors may adopt severe steps after Nuvation Bio Inc.'s (NYSE:NUVB) latest 5.9% drop adds to a year losses

July 31, 2025 | finance.yahoo.com

Nuvation Bio (NUVB) Expected to Announce Earnings on Thursday

July 31, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Trading 8.6% Higher - Should You Buy?

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX, IMTX, NUVB, and CRON Company Descriptions

Cronos Group NASDAQ:CRON

$2.56 -0.11 (-4.12%)

Closing price 04:00 PM Eastern

Extended Trading

$2.56 +0.00 (+0.20%)

As of 07:59 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Immatics NASDAQ:IMTX

$6.42 +0.08 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$6.42 +0.00 (+0.08%)

As of 04:10 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Neoleukin Therapeutics NASDAQ:NLTX

$20.35 -0.87 (-4.10%)

As of 08/11/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Nuvation Bio NYSE:NUVB

$2.32 +0.08 (+3.57%)

Closing price 03:59 PM Eastern

Extended Trading

$2.35 +0.03 (+1.08%)

As of 07:58 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time